| Code | Description | Claims | Beneficiaries | Total Paid |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
30,649 |
29,343 |
$1.92M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
22,429 |
21,750 |
$1.54M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
8,783 |
8,721 |
$881K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
9,359 |
9,097 |
$876K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
5,144 |
5,106 |
$511K |
| 99215 |
Prolong outpt/office vis |
5,399 |
4,435 |
$400K |
| 99499 |
|
8,100 |
7,970 |
$213K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,228 |
1,217 |
$133K |
| 90686 |
|
9,047 |
8,976 |
$128K |
| 99429 |
|
8,087 |
7,978 |
$73K |
| 99188 |
|
6,284 |
6,135 |
$72K |
| 90670 |
|
4,984 |
4,952 |
$68K |
| 92551 |
|
8,693 |
8,627 |
$64K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
4,004 |
3,920 |
$50K |
| 90647 |
|
3,403 |
3,374 |
$45K |
| D0120 |
Periodic oral evaluation - established patient |
2,212 |
1,782 |
$43K |
| 90723 |
|
3,173 |
3,150 |
$42K |
| D9999 |
Unspecified adjunctive procedure, by report |
2,215 |
1,782 |
$39K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
527 |
511 |
$37K |
| 90680 |
|
2,515 |
2,506 |
$35K |
| D1206 |
Topical application of fluoride varnish |
1,987 |
1,693 |
$34K |
| 90633 |
|
1,957 |
1,942 |
$28K |
| 96127 |
|
3,549 |
3,345 |
$21K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
423 |
410 |
$19K |
| 99233 |
Prolong inpt eval add15 m |
332 |
77 |
$14K |
| 90697 |
|
869 |
861 |
$14K |
| 99173 |
|
5,862 |
5,813 |
$10K |
| 90671 |
|
499 |
497 |
$10K |
| 77427 |
|
124 |
61 |
$9K |
| 90677 |
|
756 |
743 |
$9K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
510 |
504 |
$7K |
| 90688 |
|
398 |
398 |
$6K |
| 90656 |
|
723 |
709 |
$5K |
| 99381 |
|
39 |
39 |
$4K |
| 90651 |
|
393 |
390 |
$4K |
| 90710 |
|
256 |
256 |
$4K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
48 |
46 |
$4K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
36 |
36 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
461 |
455 |
$3K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
81 |
13 |
$3K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
32 |
32 |
$3K |
| 90700 |
|
136 |
136 |
$2K |
| 0071A |
|
55 |
55 |
$2K |
| 90480 |
|
89 |
83 |
$2K |
| 96161 |
|
639 |
633 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
120 |
119 |
$2K |
| 90681 |
|
155 |
152 |
$2K |
| 0072A |
|
36 |
36 |
$2K |
| 85018 |
|
727 |
718 |
$1K |
| 99383 |
|
13 |
13 |
$1K |
| 90696 |
|
109 |
109 |
$1K |
| 90707 |
|
82 |
80 |
$1K |
| 90716 |
|
78 |
76 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
49 |
46 |
$940.58 |
| 90734 |
|
65 |
65 |
$883.86 |
| 90674 |
|
43 |
43 |
$845.01 |
| 99205 |
Prolong outpt/office vis |
12 |
12 |
$819.45 |
| 99177 |
|
227 |
226 |
$654.62 |
| 90715 |
|
49 |
49 |
$608.51 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
51 |
48 |
$550.04 |
| 90619 |
|
36 |
36 |
$504.00 |
| 81003 |
|
209 |
203 |
$427.26 |
| 99356 |
|
13 |
12 |
$328.96 |
| 96380 |
|
17 |
17 |
$234.98 |
| 90685 |
|
14 |
14 |
$227.78 |
| 73562 |
|
14 |
12 |
$201.70 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
12 |
12 |
$177.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
64 |
61 |
$20.31 |
| 90381 |
|
16 |
16 |
$0.16 |
| 1160F |
|
762 |
732 |
$0.00 |
| 81025 |
|
36 |
36 |
$0.00 |
| 1159F |
|
1,268 |
1,208 |
$0.00 |
| 99072 |
|
1,674 |
1,581 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
49 |
44 |
$0.00 |
| 3078F |
|
41 |
39 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
55 |
44 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
31 |
27 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
48 |
44 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
40 |
39 |
$0.00 |
| 90694 |
|
14 |
14 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
14 |
13 |
$0.00 |